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Abstract
Background: Pregnancy in patients on chronic hemodialysis therapy, though unlikely, does happen rarely. Intensive
hemodialysis is thought to offer a better survival advantage to the unborn child. Circulating angiogenic factors are
helpful for prognostication of pregnant patients with chronic kidney disease who are not on dialysis. Data on their
utilization in dialysis patients, however, are limited.
Case Presentation: We report the case of a patient with a history of interstitial nephritis who had a kidney transplant
that failed after 8 years due to membranous nephropathy. She was initiated on hemodialysis three sessions per week
and conceived after being on dialysis for 6 weeks. She was switched to intensive hemodialysis at 8 weeks of gestation
and had a C-section because of hypertension at 35 weeks, with delivery of a healthy girl weighing 2012 g. Serum
angiogenic factors (placental growth factor and soluble fms-like tyrosine kinase) were measured at 32, 33, and 34
weeks of gestation and at 1, 2, and 3 weeks postpartum. Serum angiogenic factors were similar to what has been
reported for patients with chronic kidney disease and were not consistent with preeclampsia.
Conclusions: Our case report expands on the literature regarding intensive hemodialysis and angiogenic factor
utilization in pregnant dialysis patients. Our case report suggests that starting intensive dialysis early in pregnancy
is safe and concentration of angiogenic factors are similar to those reported for patients without kidney disease,
except for PIGF levels, which are somewhat higher.
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ABRÉGÉ
Bien que peu probable, une grossesse chez les patientes sous dialyse chronique survient en de rares occasions.
Dans ces cas très précis, l’hémodialyse intensive est considérée comme le traitement offrant les meilleures chances
de survie pour l’enfant à naitre. Chez les patientes enceintes souffrant d’insuffisance rénale chronique, mais non
dialysée, les facteurs antiangiogéniques circulants améliorent le pronostic de la grossesse. Les données sont
toutefois limitées en ce qui concerne le cas de patientes enceintes sous dialyse. Nous discutons du cas d’une
patiente avec un historique de néphrite interstitielle et dont la transplantation rénale a échoué après 8 ans en
raison d’une glomérulite extra-membraneuse. Elle avait à ce moment entrepris une dialyse à raison de trois séances
par semaine. La patiente est tombée enceinte six semaines après le début du traitement par dialyse et a dès lors
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été transférée au traitement par l’hémodialyse intensive. Le bébé, une fille de 2 012 kg en parfaite santé, est né par
césarienne à 35 semaines de gestation, car la mère souffrait d’hypertension. Deux facteurs antiangiogéniques ; le
facteur de croissance placentaire PIGF ainsi que la tyrosine kinase sFlt-1, ont été dosés à 32, 33 et 34 semaines de
gestation de même qu’une, deux et trois semaines postpartum. Les taux mesurés se situaient à des niveaux attendus
chez les patients souffrant d’insuffisance rénale chronique et n’indiquaient pas de prééclampsie. L’étude de ce
cas particulier vient enrichir la documentation existante en regard de l’utilisation de l’hémodialyse intensive chez les
patientes enceintes. Ce cas précis laisse croire qu’il est sécuritaire pour l’enfant à naitre d’amorcer une telle procédure
dès les premières semaines de la grossesse chez une femme souffrant d’insuffisance rénale chronique. Ce cas montre
également que dans ces conditions, les concentrations sériques des facteurs antiangiogéniques s’avèrent similaires à
celles rapportées pour une femme enceinte ne souffrant d’aucune néphropathie, à l’exception du PIGF dont la
concentration est sensiblement plus élevée chez la patiente dialysée.
Background
Pregnancy in patients with end-stage renal disease
(ESRD) on dialysis therapy is uncommon. The reported
conception rate is between 1 and 7.9 % for women of
child-bearing age, but recent data indicate improvement
in conception rates as centres have intensified dialysis
regimens [1]. Patients who start dialysis during pregnancy
have a more favorable outcome than those who become
pregnant on dialysis, presumably due to the presence of
residual renal function. Furthermore, there is an associ-
ation between the hours of hemodialysis received and the
chances of a live birth [2]. Conventional hemodialysis
three times a week for 4 h in pregnant women is associ-
ated with much poorer outcomes compared to intensive
hemodialysis (greater than 36 h per week) [2]. Still, the
major morbidity and mortality for patients with chronic
kidney disease (CKD) who are pregnant is secondary to
preeclampsia (PE) [3]. PE is a placental disease which
occurs in up to 5 % of all pregnancies, but rates are
significantly higher in women with CKD [4, 5].
In the last decade, angiogenic factors such as placental
growth factor (PIGF) and soluble fms-like tyrosine kin-
ase (s-FLT-1) were found to be abnormal in the maternal
circulation in women who developed PE [6]. Emerging
data suggest that serial measurements of circulating
angiogenic factors may help predict PE and adverse
pregnancy outcomes [3, 7–10]. However, the data on
angiogenic factors in pregnant patients on hemodialysis
are limited [9, 11]. We measured PIGF and s-FLT-1 in a
pregnant patient with end-stage renal disease secondary
to interstitial nephritis whose renal transplant failed
because of de novo membranous nephropathy, and
she was started on hemodialysis therapy.
Case presentation
A 33-year-old female with a history of ESRD secondary
to interstitial nephritis had a preemptive kidney trans-
plant which failed after 8 years, secondary to biopsy-
proven de novo membranous nephropathy. She had had
a history of unprovoked pulmonary embolism 4 years
after the renal transplant and had been treated with oral
anticoagulation for 2 years. The hematology consultant
found no evidence of thrombophilia. Her cyclosporine
dose had been tapered off within 1 month of starting
dialysis. Her prednisone in a dose of 5 mg orally per day
was continued throughout pregnancy. She was found to
be 6 weeks pregnant after being on dialysis for 3 months.
This was an unplanned pregnancy. The patient had a
history of smoking but quit on learning of her preg-
nancy. She was switched to intensive hemodialysis (six
dialysis sessions per week for a total dialysis time of 45 h
per week) at 8 weeks of gestation. She received heparin
500 units i.v. per hour on dialysis to prevent dialyzer
clotting (dialyzer utilized was FX 800 Fresenius Medical
Care dialyzer), and tinzaparin for prophylaxis against
pulmonary embolism. Blood flow was kept at 300 ml/min
during dialysis, and dialysate flow was 500 ml/min. Dialys-
ate potassium concentration was 3 mmol/l, bicarbonate
concentration was kept at 25 mmol/l, and calcium concen-
tration was kept at 1.75 mmol/L. Intentionally, no dietary
restrictions were implemented. Her prenatal vitamin dose
was doubled. She was also given oral zinc 15 mg per day.
Blood work was monitored initially once weekly and then
at least once every 2 weeks. Sodium phosphate was added
to her dialysate at a concentration of 0.9 mmol/l at
12 weeks of gestation. She required increasing doses of
erythropoietin from 8 weeks of gestation and increas-
ing doses of intravenous iron from 12 weeks of gestation
to maintain her hemoglobin above 90 g/l.
In the first trimester, the patient developed symptoms of
gastritis and was started on oral pantoprazole. She had an
integrated prenatal screen (IPS) for aneuploidy which was
negative as well as alpha-fetoprotein and pregnancy-
associated plasma protein A was normal. At 19 weeks and
4 days of gestation, no structural fetal anomaly was de-
tected by ultrasound. On uterine artery Doppler, there
was no notching or abnormal pulsatility index or abnor-
mal resistive index, signs which are helpful in predicting
PE. The fetus had a normal growth curve throughout the
pregnancy (Fig. 1) and normal umbilical artery Dopplers.
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Blood pressure started to increase at 28 weeks gestation.
She was started on labetalol 100 mg orally twice per day
for systolic blood pressure in the range of 150 mmHg and
diastolic blood pressure in the range of 100 mmHg, with
good control until 33 weeks of gestation when blood pres-
sure rose again, and the labetalol dose was progressively
increased to 200 mg every 6 h. On clinical exam, she did
not have evidence of volume overload.
Because of uncontrolled blood pressure (blood pres-
sure 160/110 to 170/102) she underwent C-section at
35 weeks of gestation, and gave birth to a healthy girl
weighing 2012 g. She was not treated with magnesium
sulphate. Liver function tests and platelet counts remained
within the normal range throughout the peri-partum
period. Placental pathology revealed a normal maternal
vascular pattern. Placental weight at delivery was 306 g
(expected 352 to 516 g).
Serum PIGF and s-FLT-1 were measured at 32, 33,
and 34 weeks of pregnancy and at 1, 2, and 3 weeks
postpartum. Blood was drawn immediately prior to the
hemodialysis treatment. Both sFLT-1 and PIGF were
measured by enzyme-linked immunosorbent assay (ELISA).
The kit used for PIGF was Human ELISA Kit from
Abcam®, Toronto, and for sFlt-1 was Human ELISA Kit
from R&D Systems®, Minneapolis, MN.
All assays were performed in duplicate, according to
the manufacturer’s instructions. The results are shown
in Table 1. Serum sFLT-1 remained within the normal
range reported for patients without kidney disease, and
PIGF levels were higher than the normal range [12]
arguing against development of preeclampsia.
Discussion
We report a successful pregnancy in a patient who
became pregnant after initiation of hemodialysis therapy.
She was switched to intensive hemodialysis early in her
pregnancy. The pregnancy was well tolerated, although
her blood pressure became labile at 35 weeks of gestation.
A C-section was performed and a healthy child was
delivered weighing 2012 g.
Fertility is markedly reduced in patients with ESRD,
and pregnancy in hemodialysis patients remains uncom-
mon [13]. When pregnancy occurs, there is a high risk
of mortality and morbidity to the mother and fetus. The
outcome of such pregnancies depends on the dose of
dialysis that the pregnant woman receives. Dialysis <20 h
per week is associated with high mortality with live births
ranging from 27 to 37 %. Infant survival has improved
over the years with increasing dose of dialysis [13]. Dialy-
sis of 17 ± 5 h is associated with an infant survival rate of
approximately 50 % [2], but recent data suggest that
higher doses of dialysis (greater than 36 h per week) are
associated with decreased prematurity and improved in-
fant survival [2]. Our patient underwent dialysis 45 h per
week starting at 8 weeks gestation. Our case report there-
fore suggests that starting intensive dialysis early in
Fig. 1 Estimated fetal weight by antenatal ultrasound demonstrated normal growth curve
Table 1 Values of placental growth factor (PIGF) and soluble fms-like tyrosine kinase (s-FLT-1) and their ratio
PIGF (pg/ml) s-Flt-1 (pg/ml) sFLT-1/PIGF
Gestational week 32 2809.2 (normal 54–1312) 1084 (normal 680–8042) 0.39 (normal 0.80–86.4)
Gestational week 33 1959.8 (normal 54–1312) 1142.5 (normal 680–8042) 0.58 (normal 0.80–86.4)
Gestational week 34 1535.9 (normal 43.6–1177) 1193 (833–11,643) 1.29 (normal 1.01–109)
Post-partum 1 week 774.6 68.5 0.09
Post-partum 2 weeks 667.2 149 0.22
Post-partum 3 weeks 728.5 117.5 0.16
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pregnancy is safe, well tolerated, and may improve out-
comes as previously reported [2]. The major complication
of pregnancy on dialysis is the development of pregnancy-
induced hypertension. A diagnosis of PE has important
consequences on clinical management. The recommended
management of PE is delivery of the baby. Indeed, if severe
PE is diagnosed, the baby may need to be delivered pre-
maturely to prevent maternal complications. A clinical
diagnosis of PE is made during pregnancy in the presence
of new onset hypertension and proteinuria after 20 weeks
of gestation or in the absence of proteinuria; one of the
following is required to make the diagnosis (a) decreased
platelet count; (b) renal insufficiency; (c) abnormal liver
function tests (d) pulmonary edema, and (e) central or
visual symptoms [14]. In proteinuric patients with CKD,
the diagnosis of PE is therefore challenging. In one series,
patients with CKD who were suspected to have superim-
posed PE had kidney biopsy performed, and only 58 %
had classic histologic evidence of PE [15].
Circulating angiogenic factors may play a pathogenic
role in the development of PE [16]. These factors regu-
late placental development, including remodelling of the
spiral arteries [17]. It is thought that in PE, faulty re-
modelling of spiral arteries leads to relative hypoxemia
which increases production of sFlt-1. The increase in cir-
culating sFlt-1 induces excessive binding of free PIGF
leading to endothelial dysfunction, a hallmark of PE [16].
In the general population, high serum concentration of
sFlt-1 and low levels of PIGF predict PE before develop-
ment of clinical manifestations [16].
In patients with CKD, levels of circulating angiogenic
factors represent promising markers to assist in the diag-
nosis of PE [9]. VEGF levels have been found to be simi-
lar in patients on hemodialysis as compared to healthy
people [18]. The data on angiogenic factors in patients
on established hemodialysis are limited, and indeed, our
literature search uncovered only two case reports where
circulating angiogenic factors were measured in preg-
nant women undergoing hemodialysis. Shan et al. [19]
reported the case of a 34-year-old woman who con-
ceived 1 month before initiation of hemodialysis and
had to be delivered at 29 weeks and 2 days because of
severe hypertension. No evidence of PE was found on
pathological examination of the placenta. sFlt-1 levels
were 2468 pg/ml, which is within the normal reference
range. Shan et al. did not measure PIGF levels. Cornelis
et al. [11] reported the case of a 21-year-old female who
was started on intensive hemodialysis at 26 weeks of
gestation. She was delivered at 35 weeks and 5 days of
gestation because of sudden unexplained hypertension.
sFLT-1 and PIGF levels were monitored from 21 weeks
of gestation and remained in the normal range. Our pa-
tient was started on intensive hemodialysis at 8 weeks of
gestation and also delivered because of hypertension at
35 weeks. Other than hypertension, the patient did not
have any symptoms or signs of PE, lab parameters did
not indicate the HELLP syndrome, and there was no
intrauterine growth retardation (IUGR). Placental hist-
ology was unremarkable. The placental weight was low,
perhaps related to the patient’s smoking status or poor
vascular health with history of end-stage renal disease
and history of kidney transplant with exposure to immu-
nosuppressives. Circulating angiogenic factors were not
consistent with a diagnosis of PE. In PE superimposed
on CKD, the concentration of sFlt-1 is much higher
(median, 13,519.5 pg/ml; range 6059–34,398 pg/ml) and
PIGF levels are much lower (median, 32.6 pg/ml; range
55.9–2632 pg/ml), and the ratio of sFlt-1 to PIGF (which
has a better diagnostic accuracy for preeclampsia [12]) is
quite high (median, 435.79; range 160.9–1153.53) [9], com-
pared to the results in our patient. Although our patient de-
veloped hypertension, the etiology is unlikely to be related
to PE as a host of other factors might contribute to hyper-
tension in a dialysis patient including sodium and volume
excess, activation of the renin angiotensin system, altered
endothelial function, and increased sympathetic activity.
Thus, if we had access to the results of angiogenic factors
in real time, premature delivery may have been avoided as
there was no fetal indication for delivery and she was on a
single antihypertensive agent and a second antihypertensive
agent could have been added with close monitoring.
Conclusions
Our data add to the previous two case reports suggesting
that serum levels of angiogenic factors are similar to those
reported for patients without kidney disease, except for
PIGF levels, which are somewhat higher, consistent with
data from Cornelis et al. In summary, we report a
case of pregnancy in a woman who underwent intensive
hemodialysis and had a relatively good outcome. Despite
the presence of worsening hypertension, there was no evi-
dence of PE. We suggest that monitoring of circulating
angiogenic factors might be helpful to diagnose PE in this
population. It is also essential to establish reference
levels of these markers in pregnant patients on dialysis.
Pregnancy on dialysis remains relatively rare and reliance
on case reports such as ours will be required to guide
the utilization of angiogenic factor measurements in
dialysis patients.
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